153 related articles for article (PubMed ID: 25988877)
1. The cost-effectiveness of drug therapies to treat secondary hyperparathyroidism in renal failure: a focus on evidence regarding paricalcitol and cinacalcet.
Lorenzoni V; Trieste L; Turchetti G
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):611-24. PubMed ID: 25988877
[TBL] [Abstract][Full Text] [Related]
2. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA.
Sharma A; Marshall TS; Khan SS; Johns B
Clin Drug Investig; 2014 Feb; 34(2):107-15. PubMed ID: 24214232
[TBL] [Abstract][Full Text] [Related]
3. Comparative cost analysis of management of secondary hyperparathyroidism with paricalcitol or cinacalcet with low-dose vitamin D in hemodialysis patients.
Sharma A; Ketteler M; Marshall TS; Khan SS; Schumock GT
J Med Econ; 2013 Sep; 16(9):1129-36. PubMed ID: 23834479
[TBL] [Abstract][Full Text] [Related]
4. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective.
Garside R; Pitt M; Anderson R; Mealing S; D'Souza R; Stein K
Nephrol Dial Transplant; 2007 May; 22(5):1428-36. PubMed ID: 17308322
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].
Zawierucha J; Małyszko J; Małyszko J; Dryl-Rydzyńska T; Prystacki T; Marcinkowski W
Przegl Lek; 2016; 73(4):229-32. PubMed ID: 27526425
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological control of secondary hyperparathyroidism in hemodialysis subjects: a cost consequences analysis of data from the FARO study.
Roggeri DP; Mazzaferro S; Brancaccio D; Cannella G; Messa P; Di Luca M; Morosetti M; Costanzo AM; di Luzio Paparatti U; Cornago D; Cozzolino M;
J Med Econ; 2012; 15(6):1110-7. PubMed ID: 22702445
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients.
Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD
Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487
[TBL] [Abstract][Full Text] [Related]
8. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
9. Cost per responder analysis in patients with secondary hyperparathyroidism on dialysis treated with cinacalcet.
Belozeroff V; Lee A; Tseng S; Chiroli S; Campbell JD
J Med Econ; 2013 Sep; 16(9):1154-62. PubMed ID: 23869940
[TBL] [Abstract][Full Text] [Related]
10. [Contemporary opinions on the diagnosis and treatment of secondary hyperparathyroidism].
Zawierucha J; Małyszko J; Małyszko J; Prystacki T; Marcinkowski W; Dryl-Rydzyńska T
Przegl Lek; 2016; 73(7):497-503. PubMed ID: 29677420
[TBL] [Abstract][Full Text] [Related]
11. Economic Evaluation of Cinacalcet in the United States: The EVOLVE Trial.
Belozeroff V; Chertow GM; Graham CN; Dehmel B; Parfrey PS; Briggs AH
Value Health; 2015 Dec; 18(8):1079-87. PubMed ID: 26686794
[TBL] [Abstract][Full Text] [Related]
12. Health economic evaluation of paricalcitol(®) versus cinacalcet + calcitriol (oral) in Italy. [corrected].
Nuijten M; Roggeri DP; Roggeri A; Novelli P; Marshall TS
Clin Drug Investig; 2015 Apr; 35(4):229-38. PubMed ID: 25724153
[TBL] [Abstract][Full Text] [Related]
13. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective.
Nuijten M; Andress DL; Marx SE; Sterz R
Curr Med Res Opin; 2009 May; 25(5):1221-34. PubMed ID: 19335321
[TBL] [Abstract][Full Text] [Related]
14. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet.
Stollenwerk B; Iannazzo S; Akehurst R; Adena M; Briggs A; Dehmel B; Parfrey P; Belozeroff V
Pharmacoeconomics; 2018 May; 36(5):603-612. PubMed ID: 29392552
[TBL] [Abstract][Full Text] [Related]
15. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism.
Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F
Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780
[TBL] [Abstract][Full Text] [Related]
16. [New Active vitamin D analogs and calcimimetics to control hyperparathyroidism in chronic renal failure].
Akiba T
Clin Calcium; 2007 May; 17(5):767-71. PubMed ID: 17471008
[TBL] [Abstract][Full Text] [Related]
17. [Calcimimetics, phosphate binders, vitamin D and its analogues for treating secondary hyperparathyroidism in chronic kidney disease: guideline from the Italian Society of Nephrology].
Mazzaferro S; Cozzolino M; Marangella M; Strippoli GF; Messa P;
G Ital Nefrol; 2007; 24 Suppl 37():S107-24. PubMed ID: 17347960
[TBL] [Abstract][Full Text] [Related]
18. Long-term outcomes of cinacalcet and paricalcitol titration protocol for treatment of secondary hyperparathyroidism.
Lazar E; Hebert K; Poma T; Stankus N
Am J Nephrol; 2007; 27(3):274-8. PubMed ID: 17429197
[TBL] [Abstract][Full Text] [Related]
19. Paricalcitol versus Calcitriol + Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Chronic Kidney Disease in China: A Cost-Effectiveness Analysis.
Zhang Z; Cai L; Wu H; Xu X; Fang W; He X; Wang X; Li X
Front Public Health; 2021; 9():712027. PubMed ID: 34368073
[No Abstract] [Full Text] [Related]
20. Comparison of erythropoietin resistance in hemodialysis patients using calcitriol, cinacalcet, or paricalcitol.
Afsar B; Agca E; Turk S
J Clin Pharmacol; 2015 Nov; 55(11):1280-5. PubMed ID: 26032009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
